NYSE$KWR
Quaker Chemical Corporation · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Quaker Houghton reported a net sales increase of 13% compared to the third quarter of 2019, driven by additional net sales from the Combination and Norman Hay acquisition, but experienced a 5% decline compared to prior year pro forma net sales due to lower volumes reflecting the impact from COVID-19.
Quaker Houghton's Q3 2020 results showed a strong rebound compared to Q2, with net sales at $367.2 million, a 13% increase year-over-year. Net income was $27.3 million, and adjusted EBITDA increased 24% to $63.9 million year-over-year. The company expects gradual sequential improvement in markets and anticipates full-year adjusted EBITDA to exceed $215 million.
- Net sales increased by 13% compared to Q3 2019, reaching $367.2 million.
- Net income was $27.3 million, or $1.53 per diluted share, compared to a net loss of $13.1 million, or $0.80 per diluted share, in the prior year.
- Adjusted EBITDA increased by 24% to $63.9 million compared to $51.4 million in Q3 2019.
- The company expects adjusted EBITDA to be in the range of the third quarter result for the fourth quarter and to exceed $215 million for the full year.
Headline financials
Revenue & EPS history
Quaker Chemical · Revenue · Quarterly
$367M
Forward guidance
The company expects gradual sequential improvement in its markets, anticipating adjusted EBITDA to be in the range of Q3 results for Q4 and to exceed $215 million for the full year. They project a 20+% increase in adjusted EBITDA for 2021.
Tailwinds
- Expect gradual sequential improvement in markets.
- Anticipate a 20+% increase in adjusted EBITDA for 2021.
- Integration synergies are expected to continue to help.
- Additional cost savings actions are expected to continue to help.
- Improvement in product margins are expected to continue to help.
Headwinds
- Improvement by quarter is hard to predict given the uncertainty in the operating environment.
- Still not back to where we would have expected our business to be when we started the year.
- COVID-19 continues to negatively impact global production levels.
- Foreign exchange negatively impacted the Company’s current quarter results by approximately $0.18 per diluted share.
- Uncertainty regarding widespread availability of a vaccine.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2020
+1.5%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+0.4%
Avg return
30 days after
52%
34 / 65 earnings
Positive
+20.6%
Q2 2022
Best reaction
-10.0%
Q2 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.0% | +5.1% | +7.4% | |
| Q4 2025 | +1.1% | -13.5% | -25.8% | |
| Q3 2025 | +5.5% | +7.1% | +9.6% | |
| Q1 2025 | -2.6% | -5.8% | +2.3% | |
| Q4 2024 | +2.6% | -1.2% | -7.8% | |
| Q3 2024 | +4.2% | +3.9% | +2.0% | |
| Q2 2024 | -6.5% | -8.0% | -3.3% | |
| Q1 2024 | -1.0% | -0.2% | -3.3% | |
| Q4 2023 | +0.5% | -0.2% | +4.1% | |
| Q3 2023 | +13.0% | +14.6% | +28.9% | |
| Q2 2023 | -5.3% | -9.1% | -11.4% | |
| Q1 2023 | +11.3% | +11.5% | +7.8% | |
| Q4 2022 | +0.6% | +0.5% | -5.0% | |
| Q3 2022 | +6.4% | +19.1% | +25.1% | |
| Q2 2022 | +20.6% | +21.3% | +8.7% | |
| Q1 2022 | -2.8% | -13.4% | -5.1% | |
| Q4 2021 | -3.4% | -10.9% | -4.2% | |
| Q3 2021 | +3.6% | +3.9% | -12.3% | |
| Q2 2021 | -1.9% | +2.8% | +4.3% | |
| Q1 2021 | -0.7% | -1.6% | -1.5% | |
| Q4 2020 | -4.2% | -5.3% | -20.1% | |
| Q3 2020 | +8.9% | +22.6% | +24.2% | |
| Q2 2020 | -1.8% | +1.5% | -2.6% | |
| Q1 2020 | +7.6% | +3.8% | +21.8% | |
| Q4 2019 | +1.1% | +0.1% | -28.9% | |
| Q3 2019 | -4.2% | -7.6% | -0.6% | |
| Q2 2019 | -10.0% | -10.5% | -15.2% | |
| Q1 2019 | -3.3% | -6.6% | -18.6% | |
| Q4 2018 | -0.5% | -3.5% | -4.6% | |
| Q3 2018 | +13.3% | +13.7% | +14.6% | |
| Q2 2018 | +10.0% | +3.2% | +10.0% | |
| Q1 2018 | -2.0% | -2.4% | +3.3% | |
| Q4 2017 | +1.1% | -0.7% | -2.1% | |
| Q3 2017 | +4.8% | +3.9% | +8.1% | |
| Q2 2017 | -3.9% | -5.4% | -8.2% | |
| Q1 2017 | -0.5% | +0.0% | -3.6% | |
| Q4 2016 | +2.9% | +0.8% | -2.4% | |
| Q3 2016 | +1.9% | +2.3% | +20.0% | |
| Q2 2016 | -0.1% | +0.1% | +1.1% | |
| Q1 2016 | -1.4% | — | — | |
| Q4 2015 | +6.1% | — | — | |
| Q3 2015 | +5.1% | — | — | |
| Q2 2015 | +16.0% | — | — | |
| Q1 2015 | -5.5% | — | — | |
| Q4 2014 | -7.0% | — | — | |
| Q3 2014 | +8.7% | — | — | |
| Q2 2014 | -0.3% | — | — | |
| Q1 2014 | -2.7% | — | — | |
| Q4 2013 | +6.8% | — | — | |
| Q3 2013 | -3.1% | — | — | |
| Q2 2013 | +1.7% | — | — | |
| Q1 2013 | +8.6% | — | — | |
| Q4 2012 | +1.9% | — | — | |
| Q3 2012 | +11.6% | — | — | |
| Q2 2012 | +2.8% | — | — | |
| Q1 2011 | -1.6% | — | — | |
| Q1 2012 | +0.2% | — | — | |
| Q4 2009 | -1.6% | — | — | |
| Q4 2011 | -1.6% | — | — | |
| Q3 2010 | +3.5% | — | — | |
| Q3 2011 | +3.5% | — | — | |
| Q4 2010 | -4.3% | — | — | |
| Q2 2010 | -4.3% | — | — | |
| Q2 2011 | -4.3% | — | — | |
| Q1 2010 | -6.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro